Ablain, Julien http://orcid.org/0000-0002-4509-3568
Al Mahi, Amira
Rothschild, Harriet http://orcid.org/0000-0001-5311-2872
Prasad, Meera
Aires, Sophie
Yang, Song
Dokukin, Maxim E.
Xu, Shuyun
Dang, Michelle
Sokolov, Igor
Lian, Christine G.
Zon, Leonard I. http://orcid.org/0000-0003-0860-926X
Funding for this research was provided by:
Centre National de la Recherche Scientifique (ATIP-Avenir)
Ligue Contre le Cancer
Fondation ARC pour la Recherche sur le Cancer
Fondation Tourre
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA103846, P01 CA163222)
Melanoma Research Alliance
National Science Foundation (CMMI 1937373, CMMI 1435655)
Article History
Received: 22 July 2021
Accepted: 24 August 2022
First Online: 13 October 2022
Competing interests
: L.I.Z. is a founder and stock holder of Fate Therapeutics, CAMP4 Therapeutics, Scholar Rock, and Amagma, outside of the present work. The other authors declare no competing interests.